3,075,809 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,075,809 shares of the biotechnology company's stock, valued at approximately $4,706,000. Point72 Asset Management L.P. owned approximately 2.02% of Heron Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Nicolet Advisory Services LLC acquired a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $25,000. Argent Advisors Inc. acquired a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $31,000. Focus Partners Wealth acquired a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $31,000. Cutter & CO Brokerage Inc. boosted its position in Heron Therapeutics by 69.6% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 13,600 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Heron Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 33,063 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 10,880 shares during the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on HRTX shares. Wall Street Zen lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday. Needham & Company LLC restated a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Trading Down 1.1%

Shares of HRTX traded down $0.02 during mid-day trading on Friday, reaching $1.85. The company had a trading volume of 780,850 shares, compared to its average volume of 2,281,887. The stock has a market cap of $282.24 million, a price-to-earnings ratio of -10.28 and a beta of 1.33. The firm has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $1.83. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. As a group, equities analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.